SeaStar Medical Holding Corp (ICUCW)
US Markets · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
About SeaStar Medical Holding Corp
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 183K | 420K | 495K | 615K |
| Gross Profit | 169K | 408K | 449K | 561K |
| Operating Income | (3.6M) | (3.0M) | (3.6M) | (3.8M) |
| Net Income | (3.5M) | (2.9M) | (3.5M) | (3.7M) |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 135K | 1.2M |
| Gross Profit | 0.00 | 135K | 1.2M | |
| Operating Income | (11.6M) | (14.2M) | (17.8M) | (12.2M) |
| Net Income | (12.2M) | (26.2M) | (24.8M) | (12.2M) |